Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
117.20
-0.57 (-0.48%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,807,692
Open
117.44
Bid (Size)
117.30 (7)
Ask (Size)
117.65 (1)
Prev. Close
117.77
Today's Range
116.59 - 117.89
52wk Range
90.50 - 148.15
Shares Outstanding
N/A
Dividend Yield
1.51%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
Today 5:06 EDT
A victory for the current vice president on Nov. 5 may be bad news for three market-leading businesses.
Via
The Motley Fool
Billion-Dollar News for Eli Lilly Stock Investors
October 07, 2024
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Via
The Motley Fool
Performance
YTD
+14.78%
+14.78%
1 Month
-11.15%
-11.15%
3 Month
-18.08%
-18.08%
6 Month
-8.05%
-8.05%
1 Year
+27.31%
+27.31%
More News
Read More
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
Via
Benzinga
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
October 06, 2024
Via
Benzinga
Novo
October 06, 2024
Via
Talk Markets
Novo Nordisk's Options: A Look at What the Big Money is Thinking
October 04, 2024
Via
Benzinga
This Is What Whales Are Betting On Novo Nordisk
October 02, 2024
Via
Benzinga
Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030
October 06, 2024
Via
The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
Via
Benzinga
Exposures
Product Safety
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
October 04, 2024
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
October 04, 2024
Via
Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Via
Benzinga
Exposures
Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Via
Investor's Business Daily
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
October 03, 2024
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Via
Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
Via
Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
Via
Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
Via
Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
Via
Benzinga
3 Momentum Trades Too Good Pass Up
October 02, 2024
Via
MarketBeat
Topics
ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
Via
Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.